吉非替尼治疗老年晚期非小细胞肺癌的临床研究  

Efficacy and Safety of Gefitinib for Elderly Patients with Advanced Non - small Cell Lung Cancer

作　　者：冯金萍[1] 唐剑英[1] 赵弘卿[1] 李小村[1] 

机构地区：[1]无锡市第二人民医院呼吸内科,江苏无锡214000

出　　处：《现代保健（医学创新研究）》2008年第21期12-14,共3页

摘　　要：目的探讨吉非替尼治疗老年晚期非小细胞肺癌（NSCLC）患者的疗效和安全性。方法既往接受过化疗或放疗或不能耐受放化疗的患者，应用吉非替尼（每天250mg）治疗，直至疾病进展或有不可耐受的不良反应时为止。结果28例患者应用吉非替尼治疗，其中CR1例，PR10例，SD6例，PD11例，有效率（CR＋PR）为39．3％，疾病控制率（DCR）（CR＋PR＋SD）达60．7％。女性治疗有效率高于男性（P〈0．05）；腺癌患者有效率优于非腺癌（P〈0．05）；不吸烟患者有效率高于吸烟患者（P〈0．01）。平均随访12．3个月，MTFP为6．8个月，MST为10．3个月，1年生存率为35．2％。腺癌患者MST长于非腺癌患者（P〈0．05）。临床受益患者MST明显高于临床进展患者（P〈0．01）。不良反应主要为皮疹和腹泻，Ⅰ～Ⅱ级不良反应事件发生率为91．7％。结论吉非替尼用于治疗老年晚期NSCLC患者安全、有效。Objective To evaluate the efficacy and toxicity of gefitinib （Iressa）in non -small cell lung cancer（NSCLC） patients aged 70 years over. Methods Elderly NSCLC patients pretreated with indurable chemotherapy or radiotherapy received gefitinib treatment at a daily dose of 250 mg until disease progressed, unacceptable toxicity was observed or patients refused. Results Twenty - eight elderly patients had been enrolled in the study. Complete responses was observed in 1 case,Partial responses was observed in 10 cases;Disease stabilizations in 6 cases;the overall disease control rate（ CR ＋ PR ＋ SD） was 60. 7%. The mean follow - up period was 12.3 months. The median time to progression was 6. 8 months, the median overall survival time（MST） was 10. 3 months. One year survival rate was 35. 2%. The MST of the patients with adenocarcinoma is longer than others. The MST of the group with the symptoms improvement is higher than the group of the diease progressed. The main side effects such as mild or moderate diarrhea and skin toxicity were generally tolerable. Grade 1 -2 side effects occurred in 91.3%. Conclusions Gefitinib is a valid option and well tolerated in elderly NSCLC patients.

关 键 词：非小细胞肺癌 蛋白激酶抑制剂 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]